Modulight in Media

Research tests light-activated treatment for brain cancer

The treatment pairs photodynamic therapy — a technique that uses light to activate cancer-killing compounds — with a novel nanoparticle drug developed by Joe Huang, an associate professor in the Fischell Department of Bioengineering at the University of Maryland. Researchers observed that the nanoformulation of verteporfin, known as NanoVP, significantly increases both potency and tumor penetration [...]

Research tests light-activated treatment for brain cancer Read More »

Using Innovation to Advance Ethical and Translational Brain Cancer Research

Glioblastoma is one of the most aggressive and lethal brain cancers diagnosed in adults. In the United States alone, approximately 14,000 new glioblastoma cases are reported each year, and even with surgery, chemotherapy, and radiation, the median survival remains less than 18 months. Surgeons can remove the primary tumor mass, but they cannot eliminate the

Using Innovation to Advance Ethical and Translational Brain Cancer Research Read More »

Photoimmunotherapy for Immunosuppressed Patients and Prevalent and Commonly Known Cancers

Tumors have become more common in recent years across the world. Although immunotherapy is a precise, quick, and efficient way to treat tumors, it generates serious side effects, such as cytokine release syndrome (CRS) and neurotoxicity. Thus, the creation of an efficient and non-harmful immunotherapy approach is urgently required. Photochemical interactions—especially photodynamic therapy (PDT) and

Photoimmunotherapy for Immunosuppressed Patients and Prevalent and Commonly Known Cancers Read More »

UMD Bioengineers, Modulight Team Up to Launch Drug Photosafety Project

The Huang Laboratory in the University of Maryland Fischell Department of Bioengineering (BIOE) has partnered with Modulight Corp. to establish new standardized guidelines for drug photosafety testing. The three-year project focuses on high-throughput screening of phototoxicity and drug-dye interactions.   Read article

UMD Bioengineers, Modulight Team Up to Launch Drug Photosafety Project Read More »

Modulightin toimitusjohtajan osakkeiden arvosta on sulanut lähes 100 miljoonaa euroa – ”En ajattele tätä rahojen vaan yhtiön pitkän tähtäimen potentiaalin kautta”

Modulightin toimitusjohtaja Seppo Orsila pahoittelee yhtiön kehnoa pörssitaivalta, mutta hänen mukaansa Modulight on nyt historiansa parhaassa iskussa. Ensi vuonna luvassa voi olla jo ohjeistus.  

Modulightin toimitusjohtajan osakkeiden arvosta on sulanut lähes 100 miljoonaa euroa – ”En ajattele tätä rahojen vaan yhtiön pitkän tähtäimen potentiaalin kautta” Read More »

Tamperelaisen pörssiyrityksen johtaja: Suomen Nato-hakemus on rauhoittanut kansainvälisiä asiakkaita

Modulightin toimitusjohtaja Seppo Orsila kertoo amerikkalaisten yhtiöiden suhtautuneen hermostuneesti Suomen kanssa tehtävään bisnekseen, kun Venäjä hyökkäsi helmikuussa Ukrainaan. Hän pitää Suomen kansainvälisen liiketoiminnan kannalta hyvin tärkeänä, että Suomi liittyy pian Natoon.

Tamperelaisen pörssiyrityksen johtaja: Suomen Nato-hakemus on rauhoittanut kansainvälisiä asiakkaita Read More »

Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives

Simple Summary Photodynamic therapy (PDT) is a light-activated treatment modality, which is being clinically used and further developed for a number of premalignancies, solid tumors, and disseminated cancers. Nanomedicines that facilitate PDT (photonanomedicines, PNMs) have transformed its safety, efficacy, and capacity for multifunctionality. This review focuses on the state of the art in deep-tissue activation

Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives Read More »

Scroll to Top